Caboxamycin Inhibits Heart Inflammation in a Coxsackievirus B3-Induced Myocarditis Mouse Model

Area of Science:

• Virology
• Microbiology
• Pharmacology

Background:

• Coxsackievirus B3 (CVB3) is a major cause of human myocarditis and pancreatitis.
• Current treatments and vaccines for CVB3 are lacking.
• Marine-derived compounds offer potential therapeutic avenues.

Purpose of the Study:

• To investigate the antiviral activity of caboxamycin against CVB3.
• To elucidate the mechanism of action of caboxamycin in CVB3 infection.
• To evaluate the therapeutic potential of caboxamycin in a CVB3 myocarditis model.

Main Methods:

• In vitro antiviral assays using CVB3-infected HeLa cells.
• Western blot analysis to assess viral protein production and host factor cleavage.
• Quantitative analysis of viral RNA.
• Assessment of apoptosis-related molecule cleavage.
• In vivo studies using a CVB3-induced myocarditis mouse model.

Main Results:

• Caboxamycin significantly reduced CVB3 VP1 production and eIF4G1 cleavage.
• Viral positive and negative strand RNA levels were dramatically decreased by caboxamycin.
• Cleavage of pro-apoptotic molecules (BAD, BAX, caspase3) was inhibited.
• Caboxamycin treatment improved survival rates in mice.
• Reduced myocardial damage and inflammatory cell infiltration were observed in treated mice.

Conclusions:

• Caboxamycin exhibits potent antiviral activity against CVB3.
• The drug mechanism involves inhibition of viral replication and host cell apoptosis.
• Caboxamycin demonstrates significant therapeutic potential for CVB3-induced myocarditis.